secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001628280-24-024405
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vanda director Chrousos fails re-election, tenders resignation after majority withhold vote
--------------------------------------------------------------------------------

- Phaedra S. Chrousos received 20,071,828 for vs 22,780,322 against; less than majority of votes cast.
- Chrousos resigned under company bylaws; Nominating/Governance Committee to decide acceptance.
- Directors Polymeropoulos and Chrousos elected; Polymeropoulos got 33,976,239 for, 8,943,623 against.
- Stockholders ratified PwC as auditor (44,750,588 for, 1,739,295 against) and approved say-on-pay.
- Equity plan amendment passed (34,411,032 for, 8,565,705 against) to increase authorized shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024024405/0001628280-24-024405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024024405/vnda-20240517.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-024405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer